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Summary
 
Topical exposure of mice to chemical allergens results in the migration of epidermal Langer-
hans cells (LCs) from the skin and their accumulation as immunostimulatory dendritic cells
(DCs) in draining lymph nodes. Epidermal cell–derived cytokines have been implicated in the
maturation and migration of LCs, but the adhesion molecules that regulate LC migration have
not been studied. We hypothesized that integrin-mediated interactions with extracellular ma-
trix components of the skin and lymph node may regulate LC/DC migration. We found that
 
a
 
6
 
 integrins and 
 
a
 
4
 
 integrins were differentially expressed by epidermal LCs and lymph node
DCs. A majority of LCs (70%) expressed the 
 
a
 
6
 
 integrin subunit, whereas DCs did not express
 
a
 
6
 
 integrins. In contrast, the 
 
a
 
4
 
 integrin subunit was expressed at high levels on DCs but at
much lower levels on LCs. The anti-
 
a
 
6
 
 integrin antibody, GoH3, which blocks binding to
laminin, completely prevented the spontaneous migration of LCs from skin explants in vitro
and the rapid migration of LCs from mouse ear skin induced after intradermal administration of
TNF-
 
a
 
 in vivo. GoH3 also reduced the accumulation of DCs in draining lymph nodes by a
maximum of 70% after topical administration of the chemical allergen oxazolone. LCs remain-
ing in the epidermis in the presence of GoH3 adopted a rounded morphology, rather than the
interdigitating appearance typical of LCs in naive skin, suggesting that the cells had detached
from neighboring keratinocytes and withdrawn cellular processes in preparation for migration,
but were unable to leave the epidermis. The anti-
 
a
 
4
 
 integrin antibody PS/2, which blocks
binding to fibronectin, had no effect on LC migration from the epidermis either in vitro or in
vivo, or on the accumulation of DCs in draining lymph nodes after oxazolone application. RGD-
containing peptides were also without effect on LC migration from skin explants.
These results identify an important role for 
 
a
 
6
 
 integrins in the migration of LC from the epi-
dermis to the draining lymph node by regulating access across the epidermal basement mem-
brane. In contrast, 
 
a
 
4
 
 integrins, or other integrin-dependent interactions with fibronectin that
are mediated by the RGD recognition sequence, did not influence LC migration from the epi-
dermis. In addition, 
 
a
 
4
 
 integrins did not affect the accumulation of LCs as DCs in draining
lymph nodes.
 
M
 
ature lymphoid dendritic cells (DCs)
 
1
 
 are derived from
immunologically immature precursors in nonlym-
phoid tissues. The best studied example of an immature
DC is the epidermal Langerhans cell (LC). LCs play impor-
tant roles in the induction of sensitization to contact aller-
gens. After topical application of allergen, LCs are induced
to migrate from the skin to the draining lymph node,
where they interact with naive T cells migrating in from
the blood. Accompanying this migration is their maturation
from an antigen-uptake and processing phenotype, typical
of immature DCs in nonlymphoid tissues (1, 2), to an anti-
gen-presenting phenotype typical of DCs in lymphoid tis-
sues (3, 4). Maturation and migration of LCs are central
events in the initiation of cutaneous immune responses to
chemical allergens. Epidermal cell–derived cytokines such
as GM-CSF and IL-1 stimulate the maturation of LCs in
vitro (5, 6). Recent studies have also identified a role for
 
1
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 BM, basement membrane; DC, dendritic
cell; ECM, extracellular matrix; GRDGS, Gly-Arg-Asp-Gly-Ser;
GRGDS, Gly-Arg-Gly-Asp-Ser; HRP, horseradish peroxidase; LC,
Langerhans cell; RGD, Arg-Gly-Asp; SA, streptavidin; VCAM, vascular
cell adhesion molecule.
  
1726
 
a
 
6
 
 Integrins and Langerhans Cell Migration
 
epidermal cell–derived cytokines in regulating LC migra-
tion from the skin to draining lymph nodes. Antibodies to
TNF-
 
a
 
 prevent the early migration of LCs from the epi-
dermis, the accumulation of DCs in draining lymph nodes,
and the development of optimum contact sensitization in
response to chemical allergens. Conversely, intradermal in-
jection of homologous recombinant TNF-
 
a
 
 stimulates the
rapid migration of LCs out of the epidermis and the accu-
mulation of DCs in draining nodes (7–9). Other cytokines
derived from epidermal cells, and in particular IL-1
 
b
 
, may
act in concert with TNF-
 
a
 
 to promote LC migration (10).
The migration of other types of leukocytes is regulated
by specific cell adhesion molecules on the cell surface. The
adhesion molecules that regulate LC migration from the
epidermis to the draining lymph nodes are poorly under-
stood. During migration, LCs dissociate from neighboring
keratinocytes, cross the underlying basement membrane
(BM) into the dermis, enter the afferent lymphatics and
subcapsular sinus leading into the draining lymph node, and
relocate in the paracortical or T cell area. In so doing, LCs
interact with several different BMs as well as with extracel-
lular matrix (ECM) components of the dermis and lymph
nodes. We hypothesized that integrins on the LC surface
may regulate LC migration from the epidermis to draining
lymph nodes.
Integrins are noncovalently linked 
 
a
 
/
 
b
 
 heterodimers
that form a large family of cell surface adhesion receptors
(11). There are 8 
 
b
 
 and 16 
 
a
 
 subunits, divided into sub-
families that share 
 
b
 
 subunits, giving rise to 22 distinct het-
erodimers. Integrins are important receptors for adhesion to
ECM proteins, although some integrins, such as the 
 
a
 
4
 
 and
 
b
 
2
 
 subunit–containing integrins on leukocytes, mediate
cell–cell adhesion. The epidermal BM comprises a complex
mixture of ECM proteins, including laminin, type IV col-
lagen, and proteoglycans (12). BMs surrounding lymphatics
have a similar composition and the paracortical region of
lymph nodes is rich in these ECM proteins as well as fi-
bronectin (13). In this study, we have used blocking anti-
bodies and peptides to determine the potential role of inte-
grin-mediated interactions with two major components of
BM and the ECM, laminin and fibronectin, in regulating
LC migration from the epidermis to draining lymph nodes.
We report that 
 
a
 
6
 
 integrins regulate the initial stages of LC
migration out of the epidermis across the underlying BM.
In contrast, the 
 
a
 
4
 
 integrin or Arg-Gly-Asp (RGD) pep-
tide–mediated interactions with fibronectin are not re-
quired.
 
Materials and Methods
 
Mice.
 
Young adult, 6–8-wk-old BALB/c mice bred in the
Specific Pathogen Free Units at either the National Institute for
Medical Research or Zeneca Pharmaceuticals were used for these
studies.
 
Antibodies.
 
The following antiintegrin antibodies were used
for these studies: PS/2 (anti–murine 
 
a
 
4
 
 integrin subunit, rat
IgG2b) from the American Type Culture Collection (Rockville,
MD); GoH3 (anti–murine 
 
a
 
6
 
 integrin subunit, rat IgG2a), pur-
chased as an affinity-purified antibody from Immunotech (Mar-
seille, France) and obtained as hybridoma supernatant from Dr.
A. Sonnenberg (Amsterdam University, Amsterdam, The Neth-
erlands); EA-1 (anti–mouse 
 
a
 
6
 
 integrin subunit, rat IgG2a), a gift
from Dr. B. Imhof (Geneva University, Switzerland); and 346-
11A (anti–mouse 
 
b
 
4
 
 integrin, rat IgG2a), purchased from Phar-
Mingen (San Diego, CA). M5/114 (anti–I-A
 
d
 
 and anti–I-E
 
d
 
, rat
IgG2b; reference 14) and NLDC-145 (anti–DEC-205, rat IgG2a;
reference 15) were used to identify LCs and DCs. MAC193 (an-
tiovine placental lactogen, rat IgG2a), from Dr. G. Butcher
(Babraham Institute, Cambridge, UK) and HRPN11/12a (anti–
horseradish peroxidase [HRP], rat IgG2b) from Dr. S. Hobbs
(Royal Marsden Hospital, London) were used as isotype-matched
control antibodies. Antibodies were purified from tissue culture
supernatants by affinity chromatography using protein G HiTrap
columns (Pharmacia Biotech AB, Uppsala, Sweden). FITC-
(Sigma Chemical Co., St. Louis, MO) and biotin- (Pierce Chem-
ical Co., Rockford, IL) conjugated forms of M5/114 were also
used in some experiments; 50 mg of FITC and 150 mg of biotin
were used per milligram of antibody for conjugation. The follow-
ing were used as secondary antibodies: PE-conjugated anti–rat Ig
(Southern Biotechnology Associates, Birmingham, AL), FITC-
conjugated anti–rat Ig (Sigma Chemical Co.), HRP-conjugated
anti–rat Ig (DAKO Corp., Carpinteria, CA), and streptavidin
(SA) conjugated to either HRP (DAKO Corp.) or PE (Southern
Biotechnology Associates) were used to detect biotinylated re-
agents.
 
Peptides.
 
Gly-Arg-Gly-Asp-Ser (GRGDS) and the control
peptide Gly-Arg-Asp-Gly-Ser (GRDGS) were synthesized on a
model 430A peptide synthesizer (Perkin-Elmer Corp., Norwalk,
CT) using FastMoc
 
TM
 
 chemistry.
 
Chemicals and Exposure.
 
The skin-sensitizing chemical oxazolone
(4-ethoxymethylene-2-phenyloxazol-5-one; Sigma Chemical Co.)
was dissolved in a 4:1 mixture of acetone/olive oil. Groups of
mice received 25 
 
m
 
l of either 1 or 0.5% oxazolone on the dorsum
of each ear.
 
Cytokine Administration.
 
Recombinant murine TNF-
 
a
 
 (spe-
cific activity: 2 
 
3
 
 10
 
8
 
 U/mg by L929 cytotoxicity assay) was ob-
tained from Genzyme Corp. (Cambridge, MA) as a sterile solu-
tion in PBS containing 0.1% BSA as carrier protein. Preparations
were diluted with sterile PBS containing 0.1% BSA and adminis-
tered using 1-ml syringes with 30-gauge stainless steel needles.
Mice received 30 
 
m
 
l (50 ng) intradermal injections of cytokine
into both ear pinnae. Controls included untreated mice or mice
which had received an equivalent volume of carrier protein
alone.
 
Antibody Treatment.
 
Mice were injected intraperitoneally with
100 
 
m
 
l of anti-
 
a
 
6
 
 integrin antibody (GoH3, at 100, 200, or 400
 
m
 
g/ml) or anti-
 
a
 
4
 
 integrin antibody (PS/2 at 200, 400, or 1,000
 
m
 
g/ml). Animals treated with 100 
 
m
 
g anti-
 
a
 
4
 
 antibody received a
second intraperitoneal injection of 100 
 
m
 
g 8 h after oxazolone
treatment. Control mice were injected intraperitoneally with
equal amounts of isotype-matched control antibody (MAC193 or
HRPN) diluted in sterile PBS. In some experiments both ear pinnae
were injected intradermally with 12 
 
m
 
g of anti-
 
a
 
6
 
 integrin anti-
body (GoH3) or control antibody (MAC193) in 30 
 
m
 
l of sterile
PBS. In all experiments, one group of animals was left untreated.
 
Preparation of Epidermal Cell Suspensions.
 
Ears from naive mice
were separated into dorsal and ventral halves with forceps. Dorsal
ear halves were incubated in 0.5% trypsin 1:250 (Sigma Chemical
Co.) in HBSS (GIBCO BRL, Bethesda, MD) for 20 min at
37
 
8
 
C. Epidermal sheets were removed with forceps and washed
three times in RPMI 1640 growth medium (Sigma Chemical Co.), 
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supplemented with 25 mM Hepes, 50 
 
m
 
g/ml streptomycin, 50
U/ml penicillin, 2 mM glutamine (RPMI), and 20% (vol/vol)
heat-inactivated (56
 
8
 
C for 30 min) FCS. Single cell suspensions
of epidermal cells were prepared by mechanical disaggregation of
the sheets through a stainless steel gauze. The cells were washed
twice and resuspended in RPMI containing 10% FCS (RPMI-
FCS) for flow cytometry.
 
Isolation and Enrichment of Lymph Node DCs.
 
18 h after topi-
cal application of oxazolone, DCs were isolated from auricular
lymph nodes as previously described (16). In brief, mice were
killed by CO
 
2
 
 inhalation, lymph nodes were pooled for each ex-
perimental group, and a suspension of lymph node cells was pre-
pared by mechanical disaggregation through a stainless steel
gauze. Cells were washed with 10 ml RPMI-FCS, centrifuged
for 5 min at 300 
 
g
 
, and then resuspended in RPMI-FCS at 5 
 
3
 
10
 
6
 
/ml. DCs were enriched by density gradient centrifugation. 2
ml of Metrizamide (Nycomed, Oslo, Norway) at 14.5% in
RPMI-FCS was layered under 8 ml of lymph node cells and cen-
trifuged (600 
 
g
 
) for 15 min at room temperature. Interface cells
(the low buoyant density fraction) were collected, washed once,
and resuspended in RPMI-FCS. DCs were analyzed by flow cy-
tometry or were assessed by direct morphological examination
using phase-contrast microscopy to determine the frequency of
DCs in low buoyant density fractions. DC frequencies are ex-
pressed as number of DCs per node.
 
Flow Cytometric Analysis.
 
Epidermal LCs and lymph node DCs
were identified and analyzed for the presence of various cell sur-
face markers by dual color immunofluorescent staining. Cells
(10
 
5
 
) were resuspended in PBS containing 0.2% BSA and 0.3%
sodium azide (PBA) and incubated on ice with primary antibody
for 30 min. Cells were washed and centrifuged (300 
 
g
 
 for 5 min)
twice with 2 ml of PBA, resuspended in PBA containing either
PE-conjugated anti–rat Ig plus 10% normal mouse serum or PE-
SA for biotinylated antibodies, and then cells were incubated for
30 min on ice. Cells were washed once with 2 ml of PBA and
then resuspended in PBA containing 10% normal rat serum for 10
min to block residual anti–rat Ig reactivity. After two washes to
remove rat serum, cells were incubated for 30 min with FITC-
conjugated M5/114 (to identify LCs or DCs) and washed twice,
and then a minimum of 10,000 cells were analyzed on a FAC-
Star
 
Ò
 
 flow cytometer. Data were analyzed using FACSplot
 
Ò
 
 soft-
ware developed by John Green (Computing Laboratory, Na-
tional Institute for Medical Research).
 
Skin Explant Assay.
 
Naive mice were killed by CO
 
2
 
 inhala-
tion and the ears were cut at the base with scissors. The ears were
washed twice with PBS and once with 70% ethanol. Under ster-
ile conditions, ears were spread out on a petri dish, allowed to
dry, and then split into dorsal and ventral halves with forceps.
The dorsal halves were floated individually on 2 ml of RPMI-
FCS, or on RPMI-FCS containing antibody or peptide in 16-
mm-diameter wells of 24-well cluster trays (Costar Corp., Cam-
bridge, MA). The explants were incubated at 37
 
8
 
C in a 5% CO
 
2
 
incubator. At various times, explants were removed and epider-
mal sheets were prepared and analyzed for the presence of LCs as
described below. In experiments designed to test the effect of pep-
tide or antibody on LC migration, three skin explants were used
for each treatment. Control explants were also established in trip-
licate.
 
Preparation and Analysis of Epidermal Sheets.
 
Epidermal sheets
were prepared from naive mice, skin explants, or mice previously
exposed to TNF-
 
a
 
 by intradermal injection. Dorsal ear halves
were incubated in 0.02 M EDTA in PBS for 1–1.5 h. Epidermal
sheets were fixed in acetone for 20 min at 
 
2
 
20
 
8
 
C, washed three
times with PBS, and then incubated for 30 min at room tempera-
ture either with anti–MHC class II (M5/114) or biotinylated
anti–MHC class II (M5/114) diluted in PBS containing 0.2%
BSA. Sheets were washed three times with PBS and incubated for
30 min at room temperature with either HRP-conjugated rabbit
anti–rat Ig, FITC-conjugated goat anti–rat Ig, or HRP conju-
gated to SA for biotinylated anti–MHC class II. Sheets were
washed twice with PBS and mounted onto glass slides in Citifluor
(Citifluor Ltd., London, UK) for fluorescence analysis. For immu-
nocytochemical staining, sheets received a further wash with Tris-
HCl buffer (50 mM, pH 7.4), and were developed with 1.5 mM
diaminobenzidine (Sigma Chemical Co.) in Tris-HCl buffer for
10 min and washed for a minimum of 10 min with tap water.
The sheets were then mounted onto glass microscope slides, left
to dry for 2 h, dehydrated in alcohol, cleared in Histoclear (Na-
tional Diagnostics, Atlanta, GA), and mounted in DPX.
LCs were enumerated by counting MHC class II positive cells
in epidermal sheets. For immunohistochemical analysis, six areas
were chosen at random for each of three sheets, photographed at
a magnification of 200, and the number of MHC class II positive
cells was counted per photograph, which corresponded to an area
of 0.16 mm
 
2
 
. Cell frequency was converted to LC/mm
 
2
 
 and re-
sults expressed as mean 
 
6
 
 SD. For fluorescence analyses, the fre-
quency of stained cells was assessed at a magnification of 100 us-
ing an eyepiece with a calibrated grid of 0.068 mm
 
2
 
. 4 epidermal
sheets were prepared from each experimental group, and for each
sheet 10 random consecutive fields were examined. Cell fre-
quency was converted to Lc/mm
 
2
 
 and results expressed as mean
 
6
 
 SD. The statistical significance of differences between experi-
mental groups was calculated using Student’s 
 
t
 
 test.
 
Results
 
Differential Expression of Integrin Subunits by LCs and
DCs.
 
We hypothesized that LCs may use distinct integrin
adhesion receptors to interact with the underlying BM and
other ECM proteins in skin and/or lymph nodes during
migration from the skin to draining lymph nodes. We
therefore examined epidermal LCs and lymph node DCs
for the expression of integrins that mediate adhesion to two
of the major components of BM and ECM, laminin and fi-
bronectin (Fig. 1).
LCs were isolated from the ears of naive mice and distin-
guished from other epidermal cells by MHC class II ex-
pression (5, 6). The majority (
 
.
 
70%) of LCs expressed 
 
a
 
6
 
and 
 
b
 
4
 
 integrin subunits. The expression of 
 
a
 
6
 
 integrins was
determined using two different mAbs, GoH3 and EA-1,
which gave similar results. The staining pattern obtained
with GoH3 was similar using either affinity-purified anti-
body or hybridoma supernatant. The majority of class II neg-
ative epidermal cells, which are primarily keratinocytes, ex-
pressed 
 
a
 
6 and b4 integrin subunits, as previously reported
(17). The expression of a4 integrin subunit was not detect-
able on isolated LCs, or on other epidermal cells. The ex-
pression of NLDC-145 antigen (DEC-205) was also not
detectable on isolated LCs. DCs were isolated from drain-
ing (auricular) lymph nodes of oxazolone-sensitized mice
and identified according to size, granularity, expression of
NLDC-145, and by high levels of MHC class II expression
(Fig. 1; references 14 and 18). In contrast to LCs, lymph node1728 a6 Integrins and Langerhans Cell Migration
DCs expressed the a4 integrin subunit, but did not express
a6 or b4 integrin subunits. Expression of the a4 integrin or
NLDC-145 was no longer detectable on DCs after incuba-
tion in 0.5% trypsin for 20 min, thus, the lack of a4 inte-
grin and NLDC-145 expression on LCs could reflect loss
of these epitopes during the enzyme digestion used to iso-
late LCs. In fact, immunocytochemical staining of epider-
mal sheets showed that LCs in situ express high levels of
NLDC-145 (data not shown). A comparison between LCs
in situ and cytocentrifuged preparations of isolated DCs
showed that LCs expressed much lower levels of the a4 in-
tegrin than did isolated lymph node DCs (data not shown).
In summary, the majority of LCs expressed the a6 and b4
integrin subunits whereas DCs did not express either a6 or
b4 integrins. Lymph node DCs expressed the a4 integrin
subunit, but much lower levels were found on LCs.
Antibodies to a6 but not to a4 Integrin Subunit Block the Mi-
gration of LCs from Skin Explants. The differential expres-
sion of a6 and b4 integrin subunits by LCs and lymphoid
Figure 2. The effect of anti-a6
and anti-a4 integrin antibodies
on the migration of epidermal
LCs in vitro. Skin explants were
derived from the ears of naive
mice and incubated on medium
containing either (A) anti-a6
(GoH3) or (B) anti-a4 (PS/2) in-
tegrin antibodies at 10, 50, or 100
mg/ml (solid bars). Controls in-
cluded explants cultured on me-
dium containing either no anti-
body (open bars) or isotype-
matched control antibody at 100
mg/ml (hatched bars). Epidermal
sheets were prepared from fresh
ear skin (0 h) and explants after
72 h of incubation and the num-
ber of LCs/mm2 determined by
immunohistochemistry. The re-
sults are expressed as means 6 SD
(n 5 18). At all concentrations
tested, in cultures containing
anti-a6 antibodies, the frequency
of LCs did not differ significantly
from that found in fresh explants.
These same values were signifi-
cantly (P ,0.0001) higher than
those found in fresh explants cul-
tured for 72 h in the absence of
antibody, or with an isotype-
matched control antibody (A). Similar treatment of explant cultures with
anti-a4 antibody failed to result, at any concentration, in a significant in-
crease in LC numbers compared with controls (B).
Figure 1. (A) Expression of a6 and b4 integrin subunits on LCs. Epi-
dermal cell suspensions were prepared from the ears of naive mice by
treatment with 0.5% trypsin and LCs were identified by the expression of
MHC class II. The expression of integrin subunits was determined using
antibodies to a6 (GoH3 or EA-1) or b4 subunits in comparison with an
isotype-matched control antibody (IgG2a). Results show log fluorescence
(0–104 channels) for MHC class II (x axis) and integrin subunit (y axis).
The percentage of cells within each quadrant is given. (B) Expression of
a4, a6, and b4 integrin subunits on lymph node DCs. DCs were enriched
from the draining lymph nodes of oxazolone-treated mice by density gra-
dient centrifugation on Metrizamide. DCs were distinguished from lym-
phocytes by forward scatter (FSC) versus side scatter (SSC) analysis and
identified by high expression of MHC class II and dual staining for
NLDC145 antigen. Histograms show the expression of a4, a6, and b4 in-
tegrin subunits on MHC class II positive DCs (solid lines) in comparison
with isotype-matched control antibodies (dashed lines). The profiles show
log fluorescence (0–104 channels) on the x axis and cell number (0–40) on
the y axis.1729 Price et al.
DCs suggested that the a6b4 integrin may regulate the early
stages of LC migration from the epidermis. Conversely, the
higher level of expression of the a4 integrin subunit by
DCs in comparison with LCs raises the possibility that a4
integrins may be involved in DC localization within the
lymph node. To study the roles of these integrins in regu-
lating the initial stages of LC migration from the epidermis,
blocking antibodies to a6 and a4 integrin subunits were
included in the culture medium of skin explants and their
effects on LC migration were determined (Fig. 2). Affinity-
purified anti-a6 (GoH3) and anti-a4 (PS/2) integrin anti-
bodies were added to the culture medium at 10, 50, and
100 mg/ml. Control explants were incubated on culture
medium containing isotype-matched control antibody at
100  mg/ml, or on culture medium alone. Explants were in-
cubated for 72 h, the epidermis was removed, and the
number of LCs/mm2 was determined. The number of LCs
in fresh epidermis ranged from 1,000 to 1,200 LCs/mm2.
After 72 h of incubation in culture medium, this number
decreased by z70% to 300–350 LCs/mm2. Inclusion of
100 mg/ml MAC 193 (rat IgG2a) or HRPN (rat IgG2b)
had no effect on the number of LCs remaining in the epi-
dermis after 72 h and these antibodies were therefore used
as isotype-matched controls.
Inclusion of 100 mg/ml anti-a6 antibody (GoH3) in the
medium completely prevented the emigration of LCs from
skin explants over a 72-h period. The number of LCs/mm2
remaining in the epidermis (1,193 6 174) was similar to
that in fresh epidermis (1,168 6 87). Lower doses of GoH3,
down to 10 mg/ml, also substantially inhibited LC migra-
tion. The morphology of LCs remaining in the epidermis
of anti-a6 integrin antibody–treated explants differed sig-
nificantly from that of LCs in fresh epidermis (Fig. 3). LCs
in a6 integrin antibody–treated skin explants were rounded
in appearance and lacked the interdigitating cellular pro-
cesses typical of LCs in naive skin. The few LCs remaining
in skin explants incubated either in the complete absence of
antibody or in the presence of isotype-matched control an-
tibody showed similar morphologies; LCs were slightly
larger than in naive skin and showed a reduced number of
interdigitating processes. The staining for MHC class II on
LCs in a6 integrin antibody–treated skin and in control
skin explants was more intense than that on LCs in fresh
epidermal sheets.
In contrast to the a6 integrin antibody, the addition of
up to 100 mg/ml antibody to the a4 integrin subunit had
no significant effect on the migration of LCs from skin ex-
plants. The number of LCs/mm2 remaining in the epider-
mis after 72 h of incubation was 254 6 85, which was not
significantly different from epidermal sheets that had been
incubated either in the complete absence of antibody or in
the presence of the IgG2b control antibody (274 6 46; Fig.
2). Microscopic examination revealed that the few LCs re-
maining in a4 integrin antibody–treated explants were mor-
phologically similar to those in control explants incubated
either in the absence of antibody or in the presence of iso-
type-matched control antibody. As described above, LCs
were larger than in naive skin, showed reduced numbers of
interdigitating processes, and had increased expression of
MHC class II.
The Anti-a6 Integrin mAb EA-1 Does Not Affect LC Migra-
tion. The mAb EA-1 recognizes the a6 integrin subunit
and has been shown to inhibit a6 integrin–mediated bind-
ing of prothymocytes to thymic blood vessels in mice (19).
Figure 3. Immunohistochemical staining of epidermal LCs in situ. Epi-
dermal sheets were prepared either from (A) naive mice, or from skin ex-
plants that had been incubated for 72 h on (B) culture medium containing
anti-a6 integrin antibody GoH3 at 50 mg/ml, or (C) culture medium
alone. LC are stained for MHC class II using indirect immunoperoxidase
staining. Note rounded morphology of LCs in anti-a6 integrin antibody–
treated explants in comparison with interdigitating morphology of LCs in
naive skin. Magnification, 3600.1730 a6 Integrins and Langerhans Cell Migration
However, unlike GoH3, it does not block the interaction
of a6 integrins with laminin, suggesting that a6 integrins
have an alternative ligand to laminin (20). Skin explants
were incubated on culture medium containing <50 mg/ml
EA-1 and the number of LCs was determined after 24 and
72 h (Fig. 4). In contrast to the effects of GoH3, the EA-1
antibody had no effect on the migration of LCs from skin
explants even after 72 h of incubation.
Addition of GRGDS Peptide to Skin Explants Does Not Af-
fect LC Migration. We were unable to determine the ex-
pression of other integrins that may be involved in fi-
bronectin binding, such as the a5 and b1 integrin subunits,
due to lack of available antibodies. Therefore, we have
studied the potential role of the a5b1 integrin in regulating
LC migration using a pentapeptide containing the RGD
sequence which blocks a5b1 integrin–fibronectin interac-
tions (21). Skin explants were incubated on culture me-
dium alone or medium containing either the active pen-
tapeptide GRGDS or the inactive peptide GRDGS (Fig.
4). A maximum dose of peptide (500 mM) was chosen
based on previous studies (22) and this completely inhibited
the binding of EL-4 lymphoma cells to immobilized fi-
bronectin (data not shown). The number of LCs in the epi-
dermis was determined in fresh epidermal sheets and after
24 and 72 h of incubation. Neither GRGDS nor the con-
trol peptide had any effect on the migration of LCs from
the epidermis over a 72-h period.
In Vivo Administration of Antibodies to a6 Integrins, but not
a4 Integrins, Blocks LC Migration from the Epidermis. To deter-
mine whether a6 integrins play a role in the migration of
LCs from the epidermis in vivo, affinity-purified a6 inte-
Figure 4. The effect of anti-a6
integrin antibody EA-1 and
GRGDS peptide on the migra-
tion of epidermal LCs in vitro.
Skin explants were incubated on
culture medium containing: (A)
50 mg/ml EA-1 (solid bars) or
control antibody (hatched bars);
(B) 500 mM GRGDS (RGD;
solid bars) or GRDGS (RDG;
hatched bars). Additional controls
included explants incubated on
medium containing no antibody
(open bars). The number of LCs/
mm2 was determined after 24
and 72 h of incubation and com-
pared with fresh skin (0 h). Re-
sults are expressed as means 6
SD (n 5 18). Treatment of ex-
plant cultures with EA-1 anti-
body failed to cause a significant
increase in the frequency of LCs
at 24 or 72 h compared with cul-
tures containing no antibody or
an isotype-matched control anti-
body (A). Addition to explant
cultures of GRGDS also failed to
cause a significant increase in the
frequency of LCs at 24 or 72 h
compared with cultures contain-
ing no peptide or GRDGS.
Figure 5. The effect of anti-a6 and anti-a4 integrin antibodies on
TNF-a–induced epidermal LC migration in vivo. Groups of four mice
received 40 mg of (A) anti-a6 integrin (GoH3) or (B) anti-a4 integrin
(PS/2) antibody intraperitoneally. Controls either received isotype-
matched control antibody or were left untreated. 2 h after administration
of antibody, two mice per group received 30 ml injection intradermally
into both ear pinnae of 50 ng murine TNF-a in 0.1% BSA. The remain-
ing two mice received 30 ml intradermal injection of 0.1% BSA. Ears
were removed 30 min later, epidermal sheets were prepared, and the
number of LCs/mm2 was determined by immunofluorescence analysis.
Results are means 6 SD (n 5 40). Treatment of mice with TNF-a (in
both A and B) caused a significant decrease in the frequency of LCs com-
pared with either untreated controls or mice exposed to BSA alone (P
,0.005). Treatment with anti-a6 resulted in a significantly higher fre-
quency of LC compared with mice exposed to TNF-a together with an
isotype-matched control antibody (P ,0.005; A). In contrast, anti-a4
failed to affect significantly LC frequency compared with isotype controls. 
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grin antibody was administered systemically and its effect
on LC migration was determined after administration of
mouse recombinant TNF-
 
a
 
 (Fig. 5). In mice pretreated with
40 
 
m
 
g of isotype-matched control antibody (MAC 193) the
number of LCs/mm
 
2
 
 was reduced from 826 
 
6
 
 31 in naive
animals to 671 
 
6
 
 6 after administration of TNF-
 
a
 
, which
is similar to previously reported results (8). However, mice
pretreated with 40 
 
m
 
g anti-
 
a
 
6
 
 integrin antibody GoH3
showed no reduction in the frequency of LCs; the number
of LCs/mm
 
2
 
 at 833 
 
6
 
 37 was similar to that in naive ear
skin. The morphology of LCs remaining in the epidermis
of 
 
a
 
6
 
 integrin antibody–treated mice was different to that
of LCs in naive skin (Fig. 6). A proportion of LCs adopted
a rounded morphology, similar to that of LCs in 
 
a
 
6
 
 inte-
grin antibody–treated skin explants, as opposed to the in-
terdigitating appearance typical of LCs. Systemic adminis-
tration of GoH3 had no effect on the morphology of
resident LCs in untreated skin.
In contrast to the effect of anti-
 
a
 
6
 
 integrin antibody, sys-
temic administration of 40 
 
m
 
g anti-
 
a
 
4
 
 integrin antibody
PS/2 had no effect on TNF-
 
a
 
–induced LC migration from
the epidermis (Fig. 5). The morphology of LCs remaining
in the epidermis of anti-
 
a
 
4
 
 integrin antibody–treated mice
was indistinguishable from that of LCs in either naive skin
or skin from mice treated with control antibody (data not
shown).
If 
 
a
 
6
 
 integrins are required for LC migration from the
epidermis, in vivo administration of anti-
 
a
 
6
 
 integrin anti-
body should also inhibit the accumulation of DCs in drain-
ing lymph nodes. Anti-
 
a
 
6
 
 integrin antibody was adminis-
tered either systemically, or directly into the dermis of ear
skin, 2 h before topical application of oxazolone. 18 h after
exposure to oxazolone, draining auricular lymph nodes
were removed and the number of DCs per node was deter-
mined. The results from three separate experiments are pre-
sented in Fig. 7. In individual experiments, the number of
DCs in untreated, naive mice ranged from 2,000 to 5,000/
node. Topical application of oxazolone consistently in-
creased the number of DCs per lymph node by three- to
fourfold. Administration of the anti-
 
a
 
6
 
 antibody, GoH3,
Figure 6. Immunofluorescence staining of epidermal LCs in situ. Groups of mice (n 5 2) received a single 100 ml injection intraperitoneally of 40 mg
anti-a6 integrin antibody (GoH3) 2 h before intradermal injection into both ear pinnae of (A) 50 ng murine recombinant TNF-a or (B) 0.1% BSA alone.
Ears were removed 30 min later, epidermal sheets were prepared, and the morphology of LCs was assessed after indirect immunofluorescence staining for
MHC class II expression. Note the rounded morphology of LCs in TNF-a–treated ears in comparison with interdigitating morphology of LCs in con-
trols. Magnification, 3800.
Figure 7. The effect of (A) anti-a6
and (B) anti-a4 integrin antibodies on
oxazolone-induced DC accumula-
tion in lymph nodes in vivo. Anti-
body was administered to groups of
10 mice in single 100 ml injections
intraperitoneally for the 10, 20, and
200 mg doses or in single 30 ml injec-
tions intradermally into the dorsum
of both ears for 12 mg dose. The 200
mg dose of anti-a4 integrin antibody
was given in 2 3 100 mg doses 2 h
before and 8 h after oxazolone treat-
ment. Each graph represents a separate experiment and the amount of antibody received per mouse, and the method of administration is indicated below
each graph. 2 h after antibody administration, mice received 25 ml of 0.5% oxazolone on the dorsum of both ears. Draining auricular lymph nodes were
excised 18 h later and the number of DCs per lymph node was determined. Results for isotype-matched control antibody (hatched bars) and integrin an-
tibody (solid bars) are compared with untreated, naive mice (open bars).
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significantly reduced the number of DCs per lymph node.
For example, oxazolone increased the number of DCs per
node from 1,675 to 8,275 in mice treated with control an-
tibody, and intraperitoneal injection of 20 mg of GoH3 re-
duced DC accumulation to 4,353 per node, representing a
59% inhibition of DC accumulation. 10 mg of GoH3 gave
slightly less inhibition at 37% and the higher dose of 40 mg
did not further inhibit DC accumulation (data not shown).
However, 12 mg of antibody administered intradermally was
more effective, inhibiting DC accumulation by 74% (Fig. 7).
Anti-a4 antibody had no effect on LC migration from
the epidermis of skin explants, yet this integrin was ex-
pressed on lymph node DCs (Fig. 1). The possibility exists
that, rather than being necessary for migration of LCs from
the epidermis, a4 integrins are required for DC migration
into the draining lymph nodes. Therefore, it was of interest
to test the effect of the anti-a4 antibody on lymph node
DC accumulation in vivo.
A single intraperitoneal injection of 20 mg of anti-a4 an-
tibody, PS/2, had no effect on oxazolone-induced DC ac-
cumulation; the number of DCs per lymph node at 11,322
was similar to that in animals treated with control antibody
(10,355). In the second experiment, a higher dose of anti-
body was used. A total of 200 mg of anti-a4 antibody was
administered to each animal in two 100 mg doses at 2 h be-
fore and 8 h after oxazolone treatment. The numbers of
DCs in the draining lymph nodes 18 h after oxazolone
treatment were similar in control and anti-a4 antibody–
treated mice at 8,130 and 7,480, respectively. This lack of
effect was not due to insufficient amounts of functionally
blocking antibody, as lymphocytes taken from these ani-
mals were inhibited from binding to immobilized recombi-
nant vascular cell adhesion molecule (VCAM)–1 protein by
70% using standard adhesion assays (reference 23 and data
not shown). Analysis of DCs from anti-a4 antibody–treated
mice showed that the cells were saturated with antibody,
such that the staining profile of DCs was similar to that
shown in Fig. 1 (data not shown).
Discussion
In marked contrast to other types of leukocytes, LCs mi-
grate away from, not towards, a wide range of inflamma-
tory stimuli. After stimulation, LCs dissociate from neigh-
boring keratinocytes, leave their position in the epidermis,
pass through the underlying BM into the dermis, enter the
afferent lymphatics, and relocate in the T lymphocyte–rich
areas of the draining lymph node as mature DCs (24, 25).
LCs need to migrate across BMs other than the epidermal
BM, including those in the lymphatics and subcapsular si-
nus that drain into nodes, and we predicted that LCs may
use distinct cell adhesion molecules to interact with these
BMs during migration from the skin. Therefore, we have
studied the expression and function of different integrin re-
ceptors for components of the BM on epidermal LCs and
on lymph node DCs into which LCs mature.
We identified differential expression by LCs and DCs of
a6 and b4 integrin subunits, which dimerize to form a re-
ceptor for laminin, and a4 subunit–containing integrins,
which bind fibronectin as well as cell surface molecules such
as VCAM-1 (11). The a6 and b4 integrin subunits were ex-
pressed by .70% of LCs, but neither subunit could be de-
tected on lymph node DCs. The a4 integrin subunit was
expressed by all lymph node DCs. It was not possible to
quantitate a4 integrin expression by LCs after isolation, since
the a4 integrin epitope was degraded by trypsin. However,
immunocytochemical analysis of LCs in epidermal sheets
indicated much lower levels of expression than on lymph
node DCs, which agrees with Aiba et al. (26) who reported
low level of a4 integrins on murine LCs. Other authors have
reported the expression of several integrins on LCs, includ-
ing a4 and b1 integrins (26–28), but to date, the function of
these integrins on LCs has not been determined. Since a6
and a4 integrins bind to the ECM proteins laminin and fi-
bronectin, respectively (11), we considered that these inte-
grins may regulate the migration of LCs across the epider-
mal BM into the underlying dermis and/or the subsequent
localization of LC within the draining lymph nodes.
The anti-a6 integrin antibody, GoH3, completely inhib-
ited the spontaneous migration of LCs from the epidermis
of skin explants and the rapid migration of LCs from the
epidermis stimulated by TNF-a in vivo. LCs that remained
in the epidermis of a6 integrin antibody–treated skin ex-
plants had an altered morphology in comparison with LCs
in naive skin in that the cells were rounded in appearance
rather than interdigitating between keratinocytes. LCs in
the epidermis of a6 integrin antibody/TNF-a–treated mice
displayed two distinct morphologies, either a morphology
typical of LCs in unstimulated epidermis, i.e., interdigitat-
ing among keratinocytes, or a round morphology. From these
results it can be concluded that a6 integrins are necessary
for the migration of LCs from the epidermis. Since a6 inte-
grins are also expressed on keratinocytes, we cannot formally
exclude an indirect role for a6 integrins on keratinocytes in
regulating LC migration. Upon receiving a stimulus to mi-
grate, LCs may dissociate from surrounding keratinocytes,
for example by downregulating E-cadherin expression (29),
and move towards the BM, but be prevented from travers-
ing it by the anti-a6 integrin antibody GoH3, which blocks
binding to laminin. The LCs therefore become trapped in
the epidermis, but nevertheless free from keratinocytes. Ul-
trastructural analyses will be required to determine the pre-
cise location of these rounded LCs with respect to the BM.
The increased expression of MHC class II on a6 integrin–
blocked LCs suggests that they may mature in this location.
Preliminary experiments (not shown) indicate that other
markers associated with the maturation of LCs are upregu-
lated on a6 integrin–blocked LCs. The findings in this
study suggest that interactions with laminin in the BM may
not be required for LC maturation.
The mAb GoH3 blocks the interaction of a6b1 and a6b4
integrins with laminin (30). The only defined ligands to date
for a6 subunit–containing integrins are laminin (31), al-
though recent studies with the EA-1 antibody suggest the1733 Price et al.
existence of an alternative ligand. EA-1 recognizes the a6
subunit of both a6b1 and a6b4 integrins and inhibits a6 in-
tegrin–mediated migration of prothymocytes from the blood-
stream into the thymus of mice. However, EA-1 does not
inhibit a6b1 or a6b4 integrin–dependent binding to lami-
nin (19, 20). In contrast to GoH3, the EA-1 antibody did
not inhibit LC migration from the epidermis, suggesting
that a6 integrin interactions with laminin, as opposed to
other ligands, may regulate this step.
The a6 integrin subunit has two splice variant forms,
a6A and a6B, which differ in their cytoplasmic domains
(32). Both a6A and a6B associate with the b1 and b4 inte-
grin subunits to form a6Ab1, a6Bb1, a6Ab4, and a6Bb4 in-
tegrins (30). All four integrins bind to laminin and differ-
ences in the ligand binding specificities of the a6A and a6B
variants have not been detected (30). However, it is of
considerable interest which b subunit is used to form the
a6 integrin heterodimer on LCs. The results presented here
demonstrate that .70% of LCs express the a6 integrin and
.70% also express the b4 integrin. Based on this finding, it
can be speculated that the a6b4 integrin is found on .70%
of LCs, particularly as there are currently no other a sub-
units known to dimerize with the b4 subunit. However,
expression of the b1 integrin subunit on LCs also needs to
be determined. Antibodies to the mouse b1 integrin sub-
unit were not available for such analyses and therefore, we
cannot conclude which a6 integrin is used by LCs for mi-
gration. There has been one report demonstrating that all
human epidermal LCs express b1 integrin (28), however,
the same group reported a complete absence of b4 integrin
on these cells (33).
In epithelial tissues, the a6b4 integrin is a key structural
component of hemidesmosomes (34) which mediate stable
interactions between epithelial cells and the underlying BM
and are responsible, in part, for maintaining the functional
integrity of the tissue (35). The a6b4 integrin has also been
implicated in migratory events, including the migration of
keratinocytes during wound healing (36). The apparently
contradictory roles of the a6b4 integrin in the stable adhe-
sion and in the migration of keratinocytes may be ex-
plained by the finding that epidermal growth factor recep-
tor signaling in keratinocytes results in phosphorylation of
multiple tyrosine residues on the b4 cytoplasmic tail, which
causes the disruption of hemidesmosomes and a6b4 inte-
grin–mediated migration (37). A change in the activation
status of a6 integrins on LCs may regulate migration in that
the integrin is normally held in an inactive conformation
on resident LCs but after stimulation is converted to an ac-
tive conformation allowing binding to laminin, thus facili-
tating migration across the BM. Alternatively, a6 integrins
could be expressed in the active form on resident LCs but
this is of no biological relevance as LCs are trapped within
a keratinocyte matrix.
Since we were unable to determine the expression of
other integrin receptors on LCs for fibronectin (such as
a5b1), we used RGD peptides to study their potential role
in regulating LC migration. The addition of a synthetic
RGD-containing peptide to the culture medium of skin
explants had no effect on LC migration. RGD is a consen-
sus binding sequence in many integrin ligands, including fi-
bronectin, fibrinogen, vitronectin, von Willebrand factor,
and thrombospondin, but not laminin, and binding of a3b1,
a5b1, avb1, avb3, avb5, avb6, and aIIbb3 integrins to their
ligands is dependent on this sequence (11, 21). The lack of
effect of RGD peptides suggests that the a5b1 integrin, as
well as other RGD-dependent b1 and b3 integrins, does
not regulate LC migration from the epidermis.
Addition of antibodies against the a4 integrin also had no
effect on LC migration either in vitro or in vivo. Although
we could not quantitate a4 integrin expression on LCs, it
was substantially lower than on lymph node DCs. We did
not identify which of the two a4 subunit–containing inte-
grins is expressed by DC (i.e., a4b1/very late antigen
(VLA)–4, or a4b7) but the PS/2 antibody is an effective in-
hibitor of both (38, 39) and blocks binding to all ligands
identified, including fibronectin, VCAM-1, mucosal ad-
dress in cell adhesion molecule (MAdCAM)–1, and the a4
integrin subunit itself (39–41). The PS/2 antibody is also an
effective inhibitor of a4 integrins on mouse leukocytes in
vivo (42). The lack of effect of this antibody indicates that
a4 integrin–mediated interactions with fibronectin or with
any other ligand are not required for the initial stages of LC
migration from the epidermis. However, the skin explant
model used here does not study the subsequent stages of
migration of LCs into the draining lymph nodes, and for
this reason we studied the effect of integrin antibodies on
the accumulation of DCs in draining lymph nodes in vivo.
Previous studies have shown that systemic administration
of antibodies to TNF-a 2 h before sensitization with ox-
azolone inhibited the accumulation of DCs in draining
lymph nodes in response to the chemical allergen (9). There-
fore, we used a similar model to determine the effects of
anti-a6 integrin and anti-a4 integrin antibodies on DC ac-
cumulation. Intraperitoneal administration of 40 mg of
anti-a6 integrin antibody GoH3 maximally inhibited DC
accumulation by 60%. Intradermal injection of 12 mg of
GoH3 directly into the ear gave a slightly greater inhibition
of 74%. The incomplete inhibition may be explained by
the fact that some DCs may come directly from the dermis
and/or the bloodstream. Although lymph node DCs do
not express a6 integrins, it is not possible to conclude that
a6 integrin–mediated interactions are not involved in the
migration process once the cells have left the epidermis,
since we do not know precisely when a6 integrin is down-
regulated during maturation into DCs.
In contrast, saturating doses of anti-a4 integrin antibody
had no effect on DC accumulation. It is possible that this
antibody affects the precise localization of DCs within the
lymph node paracortex and further experiments are re-
quired to test this hypothesis.
In summary, this study has reported the expression of the
a6 and b4 integrin subunits on murine LCs and has demon-
strated, for the first time, the direct involvement of a6 inte-
grins in regulating LC migration from the epidermis.1734 a6 Integrins and Langerhans Cell Migration
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